Q1 net income went from $9 million to $74 million in a single year while the company simultaneously closed an $811 million asset sale and raised its full-year guidance.
Read on, and you get the full picture of whether the balance sheet cleanup and the Provider Segment growing 28% to 31%, make this healthcare platform worth adding before the market fully processes what changed this quarter.
IPO Alert (Sponsored)
Starlink — Elon Musk’s fast-growing satellite internet venture — is reportedly gearing up for a $100 billion IPO.
To put that in perspective: that’s 228X larger than Amazon’s IPO.
Legendary investor James Altucher is now revealing how everyday investors could position themselves before it hits the public market — for under $100.
He’s even giving away a FREE ticker symbol for those ready to move early.
Click here to access it now
Q1 Beat on Every Metric: Revenue Up 26%, EPS Beat by 26%, EBITDA Up 45%
BrightSpring Health Services, Inc. (NASDAQ: BTSG) reported Q1 2026 results that beat on every line. Revenue hit $3.61 billion, up 25.6%, beating consensus by 6.3%.
Adjusted EPS of $0.39 beat $0.31 expectations by 26.1%. Adjusted EBITDA of $190 million, up 44.8%, beat estimates by 11.2%. Net income went from $9 million to $74 million year over year.
The beat was broad-based. Pharmacy Solutions grew 25.2% from specialty and infusion script expansion and new limited-distribution drug wins.
Provider Services grew 27.9% on home health census growth and deeper Medicare Advantage relationships. Two segments both above 25% means the platform is firing, not just one corner of it.
Revenue $3.61B, up 25.6%, beat consensus by 6.3%: Not a photo finish.
Adjusted EPS $0.39, beat $0.31 estimate by 26.1%: Eighth consecutive earnings beat.
Adjusted EBITDA $190M, up 44.8% year over year: Grew faster than revenue.
Net income $74M vs $9M a year ago: Not incremental improvement. A different business.
Management raised full-year revenue guidance to $14.73 billion to $15.23 billion, above the prior range and above analyst consensus.
EBITDA guidance moved to $795 million to $825 million. A company that beats cleanly and still raises is telling you Q1 was not the ceiling.
Action: Buy BTSG. Eight consecutive beats plus a guidance raise is a pattern, not a coincidence. Exit if Q2 adjusted EBITDA falls below $185 million.
Market Signals (Sponsored)
Before a stock moves, people talk. Mentions increase. Sentiment shifts.
Our app listens to millions of social data points to find these shifts. Every day Stocks.News tracks thousands of stocks, flags unusual volume trades, and logs every insider filing that drops.
A company exec just publicly filed a stock trade. And it's just sitting there. Public information. Filed with the SEC.
Most people have no idea this data exists. Stocks.News shows you every single insider filing the second it drops. Who filed.
Which stock. Right there on your screen.
Click Here To Try it free for 7 days
The $811M Community Living Divestiture Cleaned Up the Balance Sheet Immediately
BrightSpring closed the Community Living sale to Sevita for $811 million in net proceeds, recording a $31.2 million gain. Leverage dropped immediately from 2.60x to 2.27x.
Proceeds go to debt paydown. Cutting leverage by a third of a turn in one quarter while growing 26% is not something most healthcare companies manage.
The Community Living sale was not a distress move.
BrightSpring is concentrating on pharmacy and home health, the two segments with the strongest growth, and exited a segment with less scale potential.
Keep the best unit economics, sell what was dragging capital efficiency down.
$811M net proceeds from the Community Living sale: Closed March 30, one day before quarter end.
Leverage dropped from 2.60x to 2.27x in one quarter: Balance sheet improvement was visible immediately.
$31.2M gain on sale recorded: The exit was at a premium, not a discount.
Quarterly interest expense runs approximately $35 million for the rest of 2026. Leverage declining while EBITDA grows means that the spread keeps widening in your favor.
Action: If Q2 leverage drops below 2.0x, add to your position. The balance sheet is cleaning up faster than guided, and the multiple does not yet reflect it.
Trading Basics (Sponsored)
Most people who try options lose money the same way.
They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter.
This free guide pulls back the curtain.
You'll see the single "sucker's bet" to avoid at all costs… plus the pro move that protects your account before you place a single trade.
Normally $29.97. Free today.
Gross Margins Expanded 180 Basis Points While Operating Income More Than Doubled
Gross profit grew 42.5% on 25.6% revenue growth. Gross margin hit 15.2%, up 180 basis points. Operating income grew 139% year over year.
These are not the same number described three ways. Revenue, margin, and operating income all accelerating simultaneously means efficiency is compounding with scale.
Limited distribution drug wins carry higher margins than standard pharmacy. Infusion scales well as volumes grow.
Home health census growth at existing locations is improving operating leverage before new locations add cost. Automation investments are starting to show up in the numbers.
Gross margin 15.2%, up 180bps year over year: The part where growth gets interesting.
Gross profit $482M, up 42.5% on 25.6% revenue growth: Margins outpacing volume.
Operating income up 139% year over year: Scale is converting faster than the top line.
Margin expansion in healthcare services is hard. Most platforms in this space accept thin margins as the cost of scale.
BrightSpring expanding margins 180 basis points while growing 25% tells you the unit economics are improving at the same time the business is getting bigger.
That is the combination you want before a multiple re-rate happens.
Action: If Q2 gross margin holds above 15%, hold or add. Below 14.5% means Q1 was mix-driven rather than structural, and you cut position size.
Provider Segment Growing 28% to 31% Annually and Raising Guidance Again
The Provider Services segment, which covers home health, home infusion, behavioral health, and rehab, generated strong Q1 results with growth of 27.9% year over year.
Management raised the full-year Provider Segment revenue guidance to $1.875 billion to $1.925 billion, implying 28% to 31.4% annual growth.
That is faster than the Pharmacy segment is growing, and it is accelerating.
Provider Segment growth is coming from three places: census growth at existing home health locations, new location openings without heavy capital, and deeper Medicare Advantage preferred network relationships.
Medicare Advantage is one of the fastest-growing parts of US healthcare, and preferred status creates contract-backed recurring volume.
Provider Segment up 27.9% in Q1: Growing faster than Pharmacy.
Full-year Provider guidance raised to $1.875B to $1.925B: 28% to 31.4% annual growth expected.
Medicare Advantage relationships expanding: Contract-backed recurring volume, not spot demand.
Home-based care costs the system less than facility-based care, which is exactly why Medicare Advantage plans push toward it.
You are not buying a segment that needs the market to change. The shift is already happening.
Action: On the Q2 call, if management reports two or more new Medicare Advantage preferred network relationships, add 10% immediately.
How BTSG Compares Against Home Health and Healthcare Services Peers
BTSG is up more than 40% year to date, while most healthcare peers are still reporting low to mid single-digit growth and managing reimbursement pressure.
BrightSpring is reporting 26% growth with margins expanding and guidance moving higher. That divergence is not random.
The specialty pharmacy positioning is the structural differentiator.
BrightSpring competes in limited distribution drugs, where pharmaceutical manufacturers select a small number of specialty pharmacies to distribute complex, high-value medications.
These are not commodity prescriptions. They are relationship-based, contract-driven, and high margin.
Winning a new LDD position creates durable recurring revenue that a standard pharmacy competitor cannot replicate by simply cutting prices.
26% revenue growth vs low to mid single digits for most peers: Not the same healthcare market for everyone.
Guidance raised while sector peers are trimming: Execution divergence is widening.
LDD exclusive distribution positions create durable competitive moats: Built on pharmaceutical manufacturer relationships.
The market is still pricing BTSG like a healthcare services roll-up rather than a specialty platform with durable advantages. Q1 results are the kind of print that starts changing that framing.
Action: If a peer home health or specialty pharmacy name reports weaker guidance at the same time as BTSG’s next beat, rotate any peer allocation into BTSG.
Trivia: Which firm did David Einhorn famously and publicly short at a major investor conference in May 2008, predicting its collapse months before it happened?
The Risks Are Specific, and Both Come Down to Reimbursement and Integration
The primary risk is reimbursement. Medicare and Medicaid rate changes compress margins faster than operational efficiency offsets them.
Management flagged IRA drug pricing provisions and generic drug conversions as known 2026 headwinds, partially baked into guidance but not fully predictable in timing.
The second risk is integration. BrightSpring made multiple acquisitions, including home health assets from Amedisys and LHC, all being integrated simultaneously while growing 26% organically.
Management says integrations are on track, but synergy timelines tend to slip. Any delay pushes full-year EBITDA toward the low end of the $795 million to $825 million range.
IRA drug pricing provisions and generic conversions are active headwinds: Included in guidance, but the magnitude is uncertain.
Multiple home health acquisitions still in integration phase: Synergy timing risk through 2026 and into 2027.
Leverage at 2.27x, still above the company’s long-term target: Debt load remains elevated even after the divestiture.
Neither risk is a business-breaker at current conditions. Both are disclosed and tracked publicly every quarter. You know exactly what to watch.
Action: Hard stop if Q2 Pharmacy gross margin drops below 14% and full-year EBITDA guidance is cut below $780 million in the same quarter. Exit without waiting.
Final Word: Beat, Raise, Divest, and Grow – All in One Quarter
Beat every estimate, raised guidance above consensus, closed an $811 million divestiture, and grew net income 722% year over year. Four things are moving in the right direction at the same time.
Buy BTSG now. Hard stop if Q2 EBITDA misses below $185 million.
Setup Scorecard
Entry Window: Current levels after the Q1 beat. The stock is already up 40%-plus year to date, but the balance sheet improvement and guidance raise are Q1 events that are still being digested.
Catalyst Watch: Q2 EBITDA vs $190M Q1 baseline, Provider Segment Medicare Advantage relationship count, Pharmacy gross margin vs 15.2% Q1 level, leverage update after Community Living proceeds deployed.
Upside Setup: Leverage drops below 2.0x, Provider Segment maintains 28%-plus growth, LDD exclusivity wins continue, gross margins hold above 15%. Multiple re-rates from services roll-up to specialty healthcare platform.
Downside Cushion: $811M divestiture proceeds going to debt, two-segment revenue diversification, eight consecutive EPS beats, EBITDA up 45% year over year, Medicare Advantage preferred network status providing contract-backed volume.
What Moves It Next: Q2 EBITDA, Provider Segment growth rate vs guidance midpoint, any new LDD exclusive distribution wins, and leverage trajectory after divestiture proceeds are deployed.
That's our coverage for today; thanks for reading! Reply to this email with feedback or any value names you want me to check out.
Best Regards,
—Noah Zelvis
Undervalued Edge
